Viz.ai Named Among Fast Company's Most Innovative Companies 2019

SAN FRANCISCO, Feb. 20, 2019 /PRNewswire/ -- Viz.ai has been named in Fast Company's annual list of the World's Most Innovative Companies. This prestigious list, announced today, recognizes businesses leading their industries and devising new solutions to the world's toughest challenges. Viz.ai was honored in the Biotech category for its use of cutting-edge artificial intelligence to synchronize stroke care, improve patient access and speed up clinical trials.

Within 1 year of FDA clearance, Viz.ai's stroke triage software is already being used by hundreds of US hospitals. Doctors with access to Viz can save critical minutes, even hours, in the triage, diagnosis and treatment of stroke. Combining groundbreaking artificial intelligence with seamless communication, Viz.ai's image analysis facilitates the fast and accurate triage of suspected large vessel occlusions in stroke patients and better collaboration between clinicians at comprehensive and referral hospitals. Viz.ai synchronizes care across the whole care team, enabling a new era of "Synchronized Care", where the right patient gets to the right doctor at the right time. Viz LVO was the first synchronized care software to receive FDA clearance, establishing a new category at the FDA called Computer-Aided Triage.

Fast Company's "Top 10 Most Innovative Companies" list has historically been a glimpse into the future of our economy, society, and world. More than three dozen Fast Company editors, reporters, and contributors selected Viz.ai out of thousands of companies surveyed.

"This recognition is yet another honor for Viz.ai and cements Viz as a leader in AI healthcare, a large and growing field that promises to save lives, reduce disability and lower costs." says Mamoon Hamid, Kleiner Perkins Partner, and Viz.ai Board Member.

Synchronized Care supports faster patient treatment, improved outcomes and lower healthcare costs. Viz.ai also promises to significantly speed up and increase the efficiency of clinical trials through its research line of products, Viz RECRUIT.

"This honor is a testimony to the incredible people at Viz.ai, the dedicated clinicians that work with us and to the strength of our mission, to improve lives by increasing access to lifesaving treatment. It's been less than a year since we received our De Novo FDA clearance, and already several leading healthcare systems throughout the country and two major clinical trials are using Viz to deliver truly synchronize care to their patients," said Dr. Chris Mansi, neurosurgeon, co-founder and CEO of Viz.ai.

This award, combined with Viz.ai's adoption by hospital systems nationwide, cements Viz.ai as a leader in a fast-growing field. In the coming years, Viz.ai plans to build on this momentum by offering innovative new tools for a broad range of diseases.

About Viz.ai, Inc.

Viz.ai, is the leader in applied artificial intelligence in healthcare. Viz.ai's mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment and improve access to care. Viz.ai's flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat.

In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO, the first-ever computer-aided triage and notification software. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral perfusion image analysis.

Viz.ai is located in San Francisco and Tel Aviv and backed by leading Silicon Valley investors, including Kleiner Perkins, Google Ventures, Innovation Endeavors and DHVC.

About FAST COMPANY

Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies and thinkers on the future of business.

SOURCE Viz.ai

Related Links

http://viz.ai